HCSC(SH:600378)2023-04-21 16:00Financial Performance - The company achieved a net profit attributable to shareholders of 1,164,886,425.27 yuan for the year 2022, with a total distributable profit of 4,455,130,492.94 yuan[3]. - The company's operating revenue for 2022 was ¥9,067,529,684.27, representing a 22.13% increase compared to ¥7,424,354,099.10 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥1,164,886,425.27, a 30.67% increase from ¥891,462,415.27 in 2021[17]. - The net cash flow from operating activities for 2022 was ¥993,840,073.13, a decrease of 13.31% compared to ¥1,146,408,768.22 in 2021[17]. - The total assets at the end of 2022 were ¥15,424,906,958.66, reflecting a 32.30% increase from ¥11,658,860,394.51 at the end of 2021[17]. - The basic earnings per share for 2022 was ¥1.2872, up 30.28% from ¥0.9880 in 2021[18]. - The weighted average return on equity for 2022 was 15.16%, an increase of 2.02 percentage points from 13.14% in 2021[18]. - The company reported non-recurring gains of ¥201,177,921.84 for 2022, compared to ¥7,341,057.27 in 2021[22]. Dividend Policy - A cash dividend of 6.40 yuan per 10 shares (including tax) will be distributed to all shareholders, totaling 583,343,236.48 yuan (including tax), which represents 50.08% of the net profit attributable to shareholders[3]. - The company maintains a stable dividend policy while considering operational funding needs[3]. - The company has a cash dividend policy that requires at least 10% of the net profit attributable to shareholders to be distributed as cash dividends each year[193]. - The company has a policy to cumulatively distribute at least 30% of the average annual net profit attributable to shareholders over any three consecutive fiscal years[193]. - The company emphasizes the importance of maintaining a stable and continuous profit distribution policy to ensure reasonable returns for investors while considering sustainable development[193]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[4]. - The company has established safety and environmental management systems to mitigate risks associated with hazardous chemicals and is committed to improving safety management levels[136]. - The company faces customer credit risks related to accounts receivable and has implemented dynamic management strategies to ensure timely collection of payments[137]. Research and Development - Research and development expenses amounted to 726 million RMB, reflecting a year-on-year increase of 17.2%[26]. - The company has established a youth technology talent pool to enhance its workforce and management capabilities[29]. - The company has undertaken a total of 210 research projects during the reporting period, including 44 national-level projects and 139 key projects independently developed by the company[83]. - The company applied for 317 patents in 2022, with 240 being domestic invention patents, and received 210 domestic patent authorizations, including 120 domestic invention patents[84]. - The company is actively involved in the research and development of new technologies and products, focusing on key core technologies[85]. Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[23]. - The company is actively expanding its market presence in the fluorochemical and electronic chemical industries, leveraging its resource advantages[30]. - The company aims to achieve significant breakthroughs in key core technologies by 2035 as part of its strategy to drive domestic demand and innovation[78]. - The company plans to enhance market development and business collaboration, focusing on optimizing pricing mechanisms and improving product structure[122]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the chemical sector[155]. Corporate Governance - All board members attended the board meeting, ensuring the integrity of the annual report[2]. - The company has established a comprehensive internal control system to ensure risk management and compliance with regulatory requirements[143]. - The company has revised its governance structure and management systems to align with the "14th Five-Year Plan" and investment management guidelines[140]. - The company held 5 shareholder meetings, 14 board meetings, and 7 supervisory board meetings during the reporting period, complying with the requirements of the Articles of Association[139]. - The company has enhanced its investor relations management system to improve transparency and communication with stakeholders[141]. Financial Health and Investments - Operating costs increased by 26.98% to CNY 6.86 billion, primarily due to rising prices of chemical raw materials[55]. - The net cash flow from investing activities saw a significant decline of 85.88%, mainly due to increased project construction investment[55]. - The company reported a total investment in equity of CNY 194,769.33 million, with an increase of CNY 46,504.48 million during the reporting period[112]. - The company has a total of 562,800 shares held at the end of the reporting period, down from 840,000 shares at the beginning[154]. - The company reported a significant increase in revenue, achieving a total of 61 billion RMB for the year 2022[155]. Leadership and Management Changes - The company reported a significant leadership change with the resignation of independent directors after their six-year term, which will take effect after the election of new independent directors[157]. - The company appointed Li Shu and Zhao Huailiang as independent director candidates for the seventh board, following the resignation of independent directors Shen Chang'e and Xu Junli due to term expiration[158]. - The company held its first extraordinary general meeting of 2023 on February 2, where it elected members for the eighth board, including Hu Dongchen as chairman and Wang Jun as vice chairman[162]. - The company has a strategic execution department director appointed in November 2022, indicating a focus on strategic initiatives[168]. - The company has a focus on research and development, with key personnel involved in various scientific and technological roles[168].